Immediate skin responses to laser and light treatments : Therapeutic endpoints: How to obtain efficacy - 14/04/16

Doi : 10.1016/j.jaad.2015.06.026

Molly Wanner, MD, MBA ^a,^⁎ , Fernanda H. Sakamoto, MD, PhD ^a,^b, Mathew M. Avram, MD, JD ^a,^b, Henry H. Chan, MD, PhD ^c, Murad Alam, MD, MBA ^d, Zeina Tannous, MD ^e, R. Rox Anderson, MD ^a,^b
^a Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
^b Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
^c Department of Medicine, University of Hong Kong, Pokfulam, Hong Kong
^d Department of Dermatology, Northwestern University, Chicago, Illinois
^e Lebanese American University School of Medicine, Beirut, Lebanon

^∗Reprint requests: Molly Wanner, MD, MBA, Department of Dermatology, Massachusetts General Hospital, 50 Staniford St, Ste 200, Boston, MA 02114.Department of DermatologyMassachusetts General Hospital50 Staniford St, Ste 200BostonMA02114

Abstract

Clinical endpoints are immediate or early tissue reactions that occur during laser treatment. They can guide the laser surgeon in delivering safe and effective laser treatment. Some endpoints act as warning signs of injury to the skin; others can indicate a therapeutic response. The first article in this series reviewed undesirable and warning endpoints, and this article focuses on desirable and therapeutic endpoints and their underlying mechanisms in laser surgery. We will also review treatments without clinical endpoints.

Le texte complet de cet article est disponible en PDF.

Key words : endpoint, immediate skin responses, laser, light, skin, therapeutic

Abbreviations used : μm, IH, IPL, KTP, Nd:YAG, PDL, RF

Plan

Introduction

Therapeutic endpoints

Vascular lesions

Port wine stains (capillary malformation)

Infantile hemangiomas

Telangiectasia

Other vascular lesions

Lasers without specific endpoints

Nonablative fractionated lasers

Ablative fractionated lasers

Nonablative (nonfractional) mid-infrared lasers

	Funding sources: None.
	Massachusetts General Hospital receives royalties from laser companies, but none are related to this manuscript. Dr Avram is on the advisory board of and is a consultant for Zeltiq, a consultant for Kythera, and an investigator for Cutera. Dr Chan receives honoraria, equipment, stock, or other financial benefits from the following companies: Allergan, Cutera, CynoSure, Solta, Syneron, Access Business Group, Zeltiq, Regeneron, Basis Medical Technologies, Lumenis, McGraw-Hill, Quanta System, Ulthera, Cytrellis, and Venus Concept. Dr Alam received a grant (PD-100-002) from OptMed paid to his employer, Northwestern University, royalties from Elsevier, and has a consulting relationship with Amway.
	Date of release: May 2016
	Expiration date: May 2019